X

Trial Profile

BOTOX® in the Treatment of Urinary Incontinence Due to Overactive Bladder in Patients 12 to 17 Years of Age

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 30 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Botulinum-Toxin-A (Primary)
Indications Overactive bladder; Urinary incontinence
Focus Registrational; Therapeutic Use
Sponsors AbbVie; Allergan

Most Recent Events

18 May 2022 Status changed from active, no longer recruiting to discontinued.
31 Mar 2022 This trial has been completed in Belgium (Date of the global end of the trial : 17-Dec-2021), according to European Clinical Trials Database record.
10 Mar 2022 This trial has been discontinued in Poland, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com